Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $68.19 and last traded at $64.50, with a volume of 392739 shares. The stock had previously closed at $64.96.
Gemini Therapeutics Stock Performance
The company has a fifty day moving average price of $52.44 and a two-hundred day moving average price of $46.34. The company has a market cap of $2.79 billion, a P/E ratio of -64.50 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
- Five stocks we like better than Gemini Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- 5 Top Rated Dividend Stocks to Consider
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Golden Cross Stocks: Pattern, Examples and Charts
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
